{
  "drugDiseasePairs": [
    {
      "id": "1",
      "drugName": "Metformin",
      "drugNdcCode": "0093-1115-01",
      "diseaseName": "Alzheimer's Disease",
      "diseaseOntologyTerm": "MONDO:0004975",
      "biologicalSuitability": 7.2,
      "unmetMedicalNeed": 9.1,
      "economicSuitability": 6.8,
      "marketSize": 8.5,
      "competitiveAdvantage": 5.9,
      "regulatoryFeasibility": 7.3,
      "clinicalRisk": 4.2,
      "compositePrioritizationScore": 7.1,
      "narrative": "Metformin, a widely used diabetes medication, shows promising neuroprotective effects through AMPK activation and reduction of neuroinflammation. Clinical studies suggest potential benefits in cognitive decline prevention, making it an attractive repurposing candidate for Alzheimer's disease.",
      "pubchemCid": "4091"
    },
    {
      "id": "2",
      "drugName": "Sildenafil",
      "drugNdcCode": "0069-4200-66",
      "diseaseName": "Pulmonary Hypertension",
      "diseaseOntologyTerm": "MONDO:0005149",
      "biologicalSuitability": 8.9,
      "unmetMedicalNeed": 8.7,
      "economicSuitability": 7.1,
      "marketSize": 6.3,
      "competitiveAdvantage": 8.2,
      "regulatoryFeasibility": 9.1,
      "clinicalRisk": 3.5,
      "compositePrioritizationScore": 7.8,
      "narrative": "Originally developed for erectile dysfunction, sildenafil's mechanism of action through PDE-5 inhibition makes it highly effective for pulmonary arterial hypertension. This represents one of the most successful drug repurposing examples, with established safety profile and clear therapeutic benefit.",
      "pubchemCid": "5281023"
    },
    {
      "id": "3",
      "drugName": "Aspirin",
      "drugNdcCode": "0536-1010-01",
      "diseaseName": "Colorectal Cancer Prevention",
      "diseaseOntologyTerm": "MONDO:0005575",
      "biologicalSuitability": 6.8,
      "unmetMedicalNeed": 7.9,
      "economicSuitability": 9.2,
      "marketSize": 9.5,
      "competitiveAdvantage": 6.1,
      "regulatoryFeasibility": 6.8,
      "clinicalRisk": 5.3,
      "compositePrioritizationScore": 7.3,
      "narrative": "Low-dose aspirin shows significant potential in colorectal cancer prevention through COX-2 inhibition and anti-inflammatory pathways. Large epidemiological studies support its chemopreventive effects, though optimal dosing and patient selection strategies require further refinement.",
      "pubchemCid": "2244"
    },
    {
      "id": "4",
      "drugName": "Thalidomide",
      "drugNdcCode": "59572-102-00",
      "diseaseName": "Multiple Myeloma",
      "diseaseOntologyTerm": "MONDO:0009693",
      "biologicalSuitability": 8.1,
      "unmetMedicalNeed": 9.3,
      "economicSuitability": 5.4,
      "marketSize": 7.2,
      "competitiveAdvantage": 7.8,
      "regulatoryFeasibility": 4.9,
      "clinicalRisk": 7.6,
      "compositePrioritizationScore": 6.7,
      "narrative": "Despite its tragic history, thalidomide's immunomodulatory and anti-angiogenic properties have proven invaluable in multiple myeloma treatment. Its complex mechanism involving cereblon modulation has opened new therapeutic avenues, though careful monitoring for serious adverse effects remains critical.",
      "pubchemCid": "5426"
    },
    {
      "id": "5",
      "drugName": "Topiramate",
      "drugNdcCode": "0555-0960-02",
      "diseaseName": "Obesity",
      "diseaseOntologyTerm": "MONDO:0011122",
      "biologicalSuitability": 5.7,
      "unmetMedicalNeed": 8.8,
      "economicSuitability": 6.9,
      "marketSize": 9.1,
      "competitiveAdvantage": 4.8,
      "regulatoryFeasibility": 6.2,
      "clinicalRisk": 6.1,
      "compositePrioritizationScore": 6.5,
      "narrative": "Originally an antiepileptic drug, topiramate's appetite suppressant effects through multiple neurotransmitter pathways make it a candidate for obesity treatment. While weight loss benefits are documented, cognitive side effects and limited long-term data present challenges for widespread adoption.",
      "pubchemCid": "5284627"
    },
    {
      "id": "6",
      "drugName": "Propranolol",
      "drugNdcCode": "0591-5520-01",
      "diseaseName": "Post-Traumatic Stress Disorder",
      "diseaseOntologyTerm": "MONDO:0005319",
      "biologicalSuitability": 6.9,
      "unmetMedicalNeed": 8.4,
      "economicSuitability": 8.1,
      "marketSize": 7.8,
      "competitiveAdvantage": 6.7,
      "regulatoryFeasibility": 5.8,
      "clinicalRisk": 4.5,
      "compositePrioritizationScore": 6.9,
      "narrative": "Beta-blocker propranolol shows promise in disrupting traumatic memory reconsolidation when administered during memory reactivation. Its ability to modulate the emotional component of memories offers a novel approach to PTSD treatment, though optimal timing and dosing protocols remain under investigation.",
      "pubchemCid": "4946"
    },
    {
      "id": "7",
      "drugName": "Doxycycline",
      "drugNdcCode": "0093-1080-01",
      "diseaseName": "Rheumatoid Arthritis",
      "diseaseOntologyTerm": "MONDO:0008383",
      "biologicalSuitability": 6.2,
      "unmetMedicalNeed": 7.6,
      "economicSuitability": 8.7,
      "marketSize": 8.2,
      "competitiveAdvantage": 5.4,
      "regulatoryFeasibility": 6.9,
      "clinicalRisk": 3.8,
      "compositePrioritizationScore": 6.7,
      "narrative": "Beyond its antibiotic properties, doxycycline demonstrates anti-inflammatory effects through matrix metalloproteinase inhibition. Early-stage rheumatoid arthritis patients may benefit from its disease-modifying potential, offering a cost-effective addition to existing therapeutic strategies.",
      "pubchemCid": "54671203"
    },
    {
      "id": "8",
      "drugName": "Valproic Acid",
      "drugNdcCode": "0591-5542-01",
      "diseaseName": "HIV Latency Reversal",
      "diseaseOntologyTerm": "MONDO:0005109",
      "biologicalSuitability": 7.8,
      "unmetMedicalNeed": 9.5,
      "economicSuitability": 5.9,
      "marketSize": 6.7,
      "competitiveAdvantage": 7.2,
      "regulatoryFeasibility": 5.3,
      "clinicalRisk": 6.8,
      "compositePrioritizationScore": 7,
      "narrative": "As a histone deacetylase inhibitor, valproic acid may reactivate latent HIV reservoirs, a crucial step in cure strategies. While in vitro results are promising, clinical trials have shown mixed results, highlighting the complexity of achieving functional HIV cure through latency reversal.",
      "pubchemCid": "3121"
    },
    {
      "id": "9",
      "drugName": "Naltrexone",
      "drugNdcCode": "65162-145-03",
      "diseaseName": "Crohn's Disease",
      "diseaseOntologyTerm": "MONDO:0005011",
      "biologicalSuitability": 5.9,
      "unmetMedicalNeed": 8.1,
      "economicSuitability": 7.4,
      "marketSize": 7.5,
      "competitiveAdvantage": 6.3,
      "regulatoryFeasibility": 6.1,
      "clinicalRisk": 4.7,
      "compositePrioritizationScore": 6.6,
      "narrative": "Low-dose naltrexone demonstrates immunomodulatory properties distinct from its opioid antagonist activity. Small studies in Crohn's disease show promising symptom reduction and mucosal healing, though larger controlled trials are needed to establish efficacy and optimal dosing regimens.",
      "pubchemCid": "5360515"
    },
    {
      "id": "10",
      "drugName": "Losartan",
      "drugNdcCode": "0006-0952-31",
      "diseaseName": "Marfan Syndrome",
      "diseaseOntologyTerm": "MONDO:0007947",
      "biologicalSuitability": 7.6,
      "unmetMedicalNeed": 8.9,
      "economicSuitability": 6.7,
      "marketSize": 5.4,
      "competitiveAdvantage": 7.5,
      "regulatoryFeasibility": 7.8,
      "clinicalRisk": 3.9,
      "compositePrioritizationScore": 6.8,
      "narrative": "Angiotensin receptor blocker losartan reduces TGF-Î² signaling, potentially slowing aortic root dilation in Marfan syndrome. Clinical trials demonstrate modest benefits in slowing progression, offering hope for this genetic connective tissue disorder with limited therapeutic options.",
      "pubchemCid": "3961"
    },
    {
      "id": "11",
      "drugName": "Colchicine",
      "drugNdcCode": "0149-0321-01",
      "diseaseName": "Pericarditis",
      "diseaseOntologyTerm": "MONDO:0002614",
      "biologicalSuitability": 8.3,
      "unmetMedicalNeed": 7.4,
      "economicSuitability": 7.8,
      "marketSize": 6.1,
      "competitiveAdvantage": 8.1,
      "regulatoryFeasibility": 8.4,
      "clinicalRisk": 4.1,
      "compositePrioritizationScore": 7.2,
      "narrative": "Ancient gout medication colchicine shows remarkable efficacy in preventing recurrent pericarditis through anti-inflammatory mechanisms. Multiple trials confirm its benefit as first-line therapy, representing a successful repurposing story that has changed clinical practice guidelines.",
      "pubchemCid": "6167"
    },
    {
      "id": "12",
      "drugName": "Pioglitazone",
      "drugNdcCode": "54868-4852-00",
      "diseaseName": "Non-Alcoholic Steatohepatitis",
      "diseaseOntologyTerm": "MONDO:0007027",
      "biologicalSuitability": 7.4,
      "unmetMedicalNeed": 9.2,
      "economicSuitability": 6.3,
      "marketSize": 8.7,
      "competitiveAdvantage": 6.8,
      "regulatoryFeasibility": 6.4,
      "clinicalRisk": 5.9,
      "compositePrioritizationScore": 7.2,
      "narrative": "PPAR-gamma agonist pioglitazone demonstrates histological improvement in NASH through insulin sensitization and anti-inflammatory effects. Despite concerns about weight gain and bone health, it remains one of few evidence-based treatments for this increasingly prevalent liver disease.",
      "pubchemCid": "4829"
    },
    {
      "id": "13",
      "drugName": "Memantine",
      "drugNdcCode": "16729-031-10",
      "diseaseName": "Obsessive-Compulsive Disorder",
      "diseaseOntologyTerm": "MONDO:0008114",
      "biologicalSuitability": 6.1,
      "unmetMedicalNeed": 7.8,
      "economicSuitability": 6.9,
      "marketSize": 7.2,
      "competitiveAdvantage": 5.7,
      "regulatoryFeasibility": 5.9,
      "clinicalRisk": 4.3,
      "compositePrioritizationScore": 6.3,
      "narrative": "NMDA receptor antagonist memantine may modulate glutamatergic hyperactivity in OCD circuits. Preliminary studies suggest benefits in treatment-resistant cases, though larger trials are needed to establish its role as augmentation therapy alongside standard treatments.",
      "pubchemCid": "4054"
    },
    {
      "id": "14",
      "drugName": "Rituximab",
      "drugNdcCode": "50242-051-01",
      "diseaseName": "Neuromyelitis Optica",
      "diseaseOntologyTerm": "MONDO:0008049",
      "biologicalSuitability": 9.1,
      "unmetMedicalNeed": 9.6,
      "economicSuitability": 4.2,
      "marketSize": 5.1,
      "competitiveAdvantage": 8.9,
      "regulatoryFeasibility": 7.6,
      "clinicalRisk": 6.2,
      "compositePrioritizationScore": 7.2,
      "narrative": "Anti-CD20 monoclonal antibody rituximab dramatically reduces relapse rates in neuromyelitis optica through B-cell depletion. Originally for lymphoma, it has become standard care for this rare autoimmune condition, demonstrating how biologics can address orphan diseases.",
      "pubchemCid": "135766325"
    },
    {
      "id": "15",
      "drugName": "Ivermectin",
      "drugNdcCode": "59762-5200-1",
      "diseaseName": "Rosacea",
      "diseaseOntologyTerm": "MONDO:0006604",
      "biologicalSuitability": 7.7,
      "unmetMedicalNeed": 6.8,
      "economicSuitability": 7.9,
      "marketSize": 6.9,
      "competitiveAdvantage": 7.4,
      "regulatoryFeasibility": 8.2,
      "clinicalRisk": 3.2,
      "compositePrioritizationScore": 6.9,
      "narrative": "Antiparasitic ivermectin's anti-inflammatory and Demodex-targeting properties make it effective in papulopustular rosacea. Topical formulation offers excellent tolerability and efficacy, representing successful repurposing from veterinary medicine to dermatology.",
      "pubchemCid": "6321424"
    },
    {
      "id": "16",
      "drugName": "Bupropion",
      "drugNdcCode": "0173-0177-55",
      "diseaseName": "Attention Deficit Hyperactivity Disorder",
      "diseaseOntologyTerm": "MONDO:0007743",
      "biologicalSuitability": 6.8,
      "unmetMedicalNeed": 7.5,
      "economicSuitability": 7.6,
      "marketSize": 8.8,
      "competitiveAdvantage": 5.9,
      "regulatoryFeasibility": 7.1,
      "clinicalRisk": 4.8,
      "compositePrioritizationScore": 6.9,
      "narrative": "Norepinephrine-dopamine reuptake inhibitor bupropion provides an alternative for ADHD patients who cannot tolerate stimulants. While less potent than first-line agents, its favorable side effect profile and concurrent mood benefits make it valuable in select populations.",
      "pubchemCid": "444"
    },
    {
      "id": "17",
      "drugName": "Spironolactone",
      "drugNdcCode": "0093-1130-01",
      "diseaseName": "Polycystic Ovary Syndrome",
      "diseaseOntologyTerm": "MONDO:0005359",
      "biologicalSuitability": 7.1,
      "unmetMedicalNeed": 8.3,
      "economicSuitability": 8.4,
      "marketSize": 8.1,
      "competitiveAdvantage": 6.6,
      "regulatoryFeasibility": 6.7,
      "clinicalRisk": 4.4,
      "compositePrioritizationScore": 7.1,
      "narrative": "Aldosterone antagonist spironolactone's anti-androgenic effects address hirsutism and acne in PCOS. While off-label, extensive clinical experience supports its use as adjunctive therapy, particularly when combined with oral contraceptives for comprehensive symptom management.",
      "pubchemCid": "5833"
    },
    {
      "id": "18",
      "drugName": "Disulfiram",
      "drugNdcCode": "54868-0453-0",
      "diseaseName": "Glioblastoma",
      "diseaseOntologyTerm": "MONDO:0018177",
      "biologicalSuitability": 6.4,
      "unmetMedicalNeed": 9.8,
      "economicSuitability": 7.2,
      "marketSize": 6.4,
      "competitiveAdvantage": 6.9,
      "regulatoryFeasibility": 5.1,
      "clinicalRisk": 7.3,
      "compositePrioritizationScore": 7,
      "narrative": "Alcohol deterrent disulfiram demonstrates unexpected anti-cancer properties through multiple mechanisms including aldehyde dehydrogenase inhibition. Early clinical data in glioblastoma is encouraging, though larger trials are needed to validate this surprising repurposing opportunity.",
      "pubchemCid": "3117"
    },
    {
      "id": "19",
      "drugName": "Levetiracetam",
      "drugNdcCode": "0131-2612-18",
      "diseaseName": "Alzheimer's Disease with Seizures",
      "diseaseOntologyTerm": "MONDO:0004975",
      "biologicalSuitability": 7.3,
      "unmetMedicalNeed": 8.5,
      "economicSuitability": 6.5,
      "marketSize": 7.1,
      "competitiveAdvantage": 6.8,
      "regulatoryFeasibility": 7.4,
      "clinicalRisk": 3.7,
      "compositePrioritizationScore": 6.8,
      "narrative": "Antiepileptic levetiracetam may reduce network hyperexcitability in early Alzheimer's disease beyond just treating seizures. Preliminary evidence suggests potential disease-modifying effects on cognition, warranting larger preventive trials in at-risk populations.",
      "pubchemCid": "441341"
    },
    {
      "id": "20",
      "drugName": "Hydroxychloroquine",
      "drugNdcCode": "0054-4747-25",
      "diseaseName": "Systemic Lupus Erythematosus",
      "diseaseOntologyTerm": "MONDO:0007915",
      "biologicalSuitability": 8.4,
      "unmetMedicalNeed": 8.6,
      "economicSuitability": 7.8,
      "marketSize": 6.8,
      "competitiveAdvantage": 7.9,
      "regulatoryFeasibility": 8.7,
      "clinicalRisk": 4.6,
      "compositePrioritizationScore": 7.5,
      "narrative": "Antimalarial hydroxychloroquine has become cornerstone therapy in lupus through immunomodulatory mechanisms. Its ability to reduce flares, protect against organ damage, and improve survival makes it indispensable despite requiring regular ophthalmologic monitoring.",
      "pubchemCid": "3652"
    },
    {
      "id": "21",
      "drugName": "Acyclovir",
      "drugNdcCode": "0781-1871-01",
      "diseaseName": "Bell's Palsy",
      "diseaseOntologyTerm": "MONDO:0001835",
      "biologicalSuitability": 5.8,
      "unmetMedicalNeed": 7.1,
      "economicSuitability": 8.3,
      "marketSize": 6.5,
      "competitiveAdvantage": 5.6,
      "regulatoryFeasibility": 7.6,
      "clinicalRisk": 3.1,
      "compositePrioritizationScore": 6.3,
      "narrative": "Antiviral acyclovir targets potential herpes simplex virus reactivation in Bell's palsy. Meta-analyses show modest benefits when combined with corticosteroids, particularly in severe cases, though controversy remains regarding universal use versus targeted therapy.",
      "pubchemCid": "2022"
    },
    {
      "id": "22",
      "drugName": "Simvastatin",
      "drugNdcCode": "0006-0740-31",
      "diseaseName": "Multiple Sclerosis",
      "diseaseOntologyTerm": "MONDO:0005301",
      "biologicalSuitability": 6.7,
      "unmetMedicalNeed": 8.7,
      "economicSuitability": 8.1,
      "marketSize": 7.8,
      "competitiveAdvantage": 5.8,
      "regulatoryFeasibility": 6.3,
      "clinicalRisk": 4.9,
      "compositePrioritizationScore": 6.9,
      "narrative": "Beyond lipid-lowering, statins demonstrate immunomodulatory and neuroprotective effects relevant to MS. High-dose simvastatin shows promise in secondary progressive MS where treatment options are limited, though myopathy risk requires careful monitoring.",
      "pubchemCid": "54454"
    },
    {
      "id": "23",
      "drugName": "Azithromycin",
      "drugNdcCode": "0093-7146-56",
      "diseaseName": "Cystic Fibrosis",
      "diseaseOntologyTerm": "MONDO:0009061",
      "biologicalSuitability": 7.9,
      "unmetMedicalNeed": 8.8,
      "economicSuitability": 7.4,
      "marketSize": 5.9,
      "competitiveAdvantage": 7.6,
      "regulatoryFeasibility": 8.1,
      "clinicalRisk": 4.2,
      "compositePrioritizationScore": 7.1,
      "narrative": "Macrolide azithromycin's anti-inflammatory and immunomodulatory properties improve lung function in CF beyond antimicrobial effects. Chronic low-dose therapy reduces exacerbations in patients colonized with Pseudomonas, changing CF maintenance treatment paradigms.",
      "pubchemCid": "447043"
    },
    {
      "id": "24",
      "drugName": "Mifepristone",
      "drugNdcCode": "0186-0800-01",
      "diseaseName": "Cushing's Syndrome",
      "diseaseOntologyTerm": "MONDO:0006644",
      "biologicalSuitability": 8.6,
      "unmetMedicalNeed": 9.1,
      "economicSuitability": 4.8,
      "marketSize": 4.7,
      "competitiveAdvantage": 8.7,
      "regulatoryFeasibility": 7.2,
      "clinicalRisk": 6.4,
      "compositePrioritizationScore": 7,
      "narrative": "Glucocorticoid receptor antagonist mifepristone offers hope for Cushing's syndrome patients unsuitable for surgery. Originally developed as abortifacient, its ability to block cortisol effects provides rapid symptom relief in this rare but devastating endocrine disorder.",
      "pubchemCid": "55245"
    },
    {
      "id": "25",
      "drugName": "Ketamine",
      "drugNdcCode": "0641-6070-25",
      "diseaseName": "Treatment-Resistant Depression",
      "diseaseOntologyTerm": "MONDO:0002050",
      "biologicalSuitability": 8.2,
      "unmetMedicalNeed": 9.4,
      "economicSuitability": 5.6,
      "marketSize": 8.3,
      "competitiveAdvantage": 8.5,
      "regulatoryFeasibility": 6.8,
      "clinicalRisk": 7.1,
      "compositePrioritizationScore": 7.7,
      "narrative": "Anesthetic ketamine's rapid antidepressant effects through NMDA receptor antagonism represent a paradigm shift in depression treatment. Intranasal esketamine offers new hope for treatment-resistant cases, though abuse potential and dissociative effects require specialized monitoring.",
      "pubchemCid": "3821"
    },
    {
      "id": "26",
      "drugName": "Pentoxifylline",
      "drugNdcCode": "0173-0447-42",
      "diseaseName": "Diabetic Nephropathy",
      "diseaseOntologyTerm": "MONDO:0005016",
      "biologicalSuitability": 6.3,
      "unmetMedicalNeed": 8.2,
      "economicSuitability": 7.6,
      "marketSize": 8.6,
      "competitiveAdvantage": 5.4,
      "regulatoryFeasibility": 6.5,
      "clinicalRisk": 3.9,
      "compositePrioritizationScore": 6.6,
      "narrative": "Phosphodiesterase inhibitor pentoxifylline demonstrates anti-inflammatory and antifibrotic effects in diabetic kidney disease. While results are mixed, some studies show reduced proteinuria and slowed progression, suggesting potential as adjunctive therapy in this common complication.",
      "pubchemCid": "4740"
    },
    {
      "id": "27",
      "drugName": "Baclofen",
      "drugNdcCode": "0591-0532-01",
      "diseaseName": "Alcohol Use Disorder",
      "diseaseOntologyTerm": "MONDO:0002046",
      "biologicalSuitability": 6.6,
      "unmetMedicalNeed": 8.9,
      "economicSuitability": 7.8,
      "marketSize": 8.7,
      "competitiveAdvantage": 6.2,
      "regulatoryFeasibility": 6.4,
      "clinicalRisk": 5.3,
      "compositePrioritizationScore": 7.1,
      "narrative": "GABA-B agonist baclofen reduces alcohol craving and consumption in some patients. European approval contrasts with mixed FDA evaluation, highlighting regional differences in evidence interpretation for this muscle relaxant's addiction treatment application.",
      "pubchemCid": "2284"
    },
    {
      "id": "28",
      "drugName": "Dapsone",
      "drugNdcCode": "54569-0649-0",
      "diseaseName": "Dermatitis Herpetiformis",
      "diseaseOntologyTerm": "MONDO:0006584",
      "biologicalSuitability": 8.8,
      "unmetMedicalNeed": 7.9,
      "economicSuitability": 7.2,
      "marketSize": 4.8,
      "competitiveAdvantage": 9.1,
      "regulatoryFeasibility": 8.3,
      "clinicalRisk": 5.7,
      "compositePrioritizationScore": 7.4,
      "narrative": "Ancient leprosy drug dapsone provides dramatic relief in dermatitis herpetiformis through unclear mechanisms. Its efficacy in this itchy blistering condition associated with celiac disease is so reliable that response to treatment serves as diagnostic confirmation.",
      "pubchemCid": "2955"
    },
    {
      "id": "29",
      "drugName": "Minoxidil",
      "drugNdcCode": "0574-0155-01",
      "diseaseName": "Androgenetic Alopecia",
      "diseaseOntologyTerm": "MONDO:0005308",
      "biologicalSuitability": 6.9,
      "unmetMedicalNeed": 6.4,
      "economicSuitability": 8.9,
      "marketSize": 9.3,
      "competitiveAdvantage": 7.8,
      "regulatoryFeasibility": 9.2,
      "clinicalRisk": 2.8,
      "compositePrioritizationScore": 7.3,
      "narrative": "Antihypertensive minoxidil's hair growth effects represent one of dermatology's most successful repurposing stories. Topical formulation minimizes cardiovascular effects while maintaining efficacy, creating a multibillion-dollar market for pattern baldness treatment.",
      "pubchemCid": "4201"
    },
    {
      "id": "30",
      "drugName": "Clomiphene",
      "drugNdcCode": "0068-0228-30",
      "diseaseName": "Male Hypogonadism",
      "diseaseOntologyTerm": "MONDO:0005337",
      "biologicalSuitability": 7.4,
      "unmetMedicalNeed": 7.7,
      "economicSuitability": 7.9,
      "marketSize": 7.4,
      "competitiveAdvantage": 7.1,
      "regulatoryFeasibility": 6.9,
      "clinicalRisk": 4.1,
      "compositePrioritizationScore": 7.1,
      "narrative": "Selective estrogen receptor modulator clomiphene stimulates endogenous testosterone production in men with secondary hypogonadism. Off-label use preserves fertility unlike testosterone replacement, appealing to younger men despite lack of FDA approval for this indication.",
      "pubchemCid": "2800"
    },
    {
      "id": "31",
      "drugName": "Amantadine",
      "drugNdcCode": "0179-0076-10",
      "diseaseName": "Traumatic Brain Injury",
      "diseaseOntologyTerm": "MONDO:0002492",
      "biologicalSuitability": 6.5,
      "unmetMedicalNeed": 8.6,
      "economicSuitability": 7.5,
      "marketSize": 7.6,
      "competitiveAdvantage": 6.4,
      "regulatoryFeasibility": 6.6,
      "clinicalRisk": 4.6,
      "compositePrioritizationScore": 6.8,
      "narrative": "Antiviral and antiparkinsonian amantadine accelerates functional recovery in patients with prolonged disorders of consciousness after TBI. Its dopaminergic and glutamatergic effects may promote neural plasticity, though optimal timing and patient selection remain unclear.",
      "pubchemCid": "2130"
    },
    {
      "id": "32",
      "drugName": "Finasteride",
      "drugNdcCode": "0006-0071-31",
      "diseaseName": "Benign Prostatic Hyperplasia",
      "diseaseOntologyTerm": "MONDO:0004645",
      "biologicalSuitability": 8.7,
      "unmetMedicalNeed": 7.8,
      "economicSuitability": 7.6,
      "marketSize": 8.9,
      "competitiveAdvantage": 8.3,
      "regulatoryFeasibility": 9.3,
      "clinicalRisk": 4.4,
      "compositePrioritizationScore": 7.9,
      "narrative": "5-alpha reductase inhibitor finasteride shrinks prostate volume and improves urinary symptoms through DHT suppression. Originally for baldness, it has become standard BPH therapy, demonstrating how hormonal mechanisms can address multiple androgen-related conditions.",
      "pubchemCid": "57363"
    },
    {
      "id": "33",
      "drugName": "N-Acetylcysteine",
      "drugNdcCode": "63323-217-10",
      "diseaseName": "Trichotillomania",
      "diseaseOntologyTerm": "MONDO:0001986",
      "biologicalSuitability": 5.4,
      "unmetMedicalNeed": 7.3,
      "economicSuitability": 8.2,
      "marketSize": 5.7,
      "competitiveAdvantage": 6.1,
      "regulatoryFeasibility": 5.8,
      "clinicalRisk": 2.9,
      "compositePrioritizationScore": 5.9,
      "narrative": "Antioxidant N-acetylcysteine modulates glutamate neurotransmission in hair-pulling disorder. Promising open-label studies suggest benefits in this challenging condition, though the single controlled trial showed mixed results, requiring larger studies to clarify efficacy.",
      "pubchemCid": "12035"
    },
    {
      "id": "34",
      "drugName": "Tamoxifen",
      "drugNdcCode": "0054-4147-25",
      "diseaseName": "Bipolar Disorder",
      "diseaseOntologyTerm": "MONDO:0004985",
      "biologicalSuitability": 5.2,
      "unmetMedicalNeed": 8.4,
      "economicSuitability": 6.8,
      "marketSize": 7.9,
      "competitiveAdvantage": 5.7,
      "regulatoryFeasibility": 4.9,
      "clinicalRisk": 6.7,
      "compositePrioritizationScore": 6.5,
      "narrative": "Selective estrogen receptor modulator tamoxifen shows antimanic properties through protein kinase C inhibition. While intriguing mechanistically, clinical evidence remains preliminary and the cancer drug's side effect profile limits enthusiasm for psychiatric repurposing without compelling efficacy data.",
      "pubchemCid": "2733526"
    },
    {
      "id": "35",
      "drugName": "Prazosin",
      "drugNdcCode": "0069-2170-68",
      "diseaseName": "PTSD-Related Nightmares",
      "diseaseOntologyTerm": "MONDO:0005319",
      "biologicalSuitability": 7.8,
      "unmetMedicalNeed": 8.2,
      "economicSuitability": 7.7,
      "marketSize": 6.9,
      "competitiveAdvantage": 7.9,
      "regulatoryFeasibility": 7.4,
      "clinicalRisk": 4.3,
      "compositePrioritizationScore": 7.2,
      "narrative": "Alpha-blocker prazosin dramatically reduces trauma-related nightmares and sleep disturbance in PTSD. Its ability to block noradrenergic activation during REM sleep provides targeted symptom relief, becoming widely prescribed despite recent negative controlled trial results.",
      "pubchemCid": "4893"
    },
    {
      "id": "36",
      "drugName": "Zoledronic Acid",
      "drugNdcCode": "0078-0483-61",
      "diseaseName": "Paget's Disease of Bone",
      "diseaseOntologyTerm": "MONDO:0005520",
      "biologicalSuitability": 9.2,
      "unmetMedicalNeed": 8.1,
      "economicSuitability": 5.8,
      "marketSize": 5.3,
      "competitiveAdvantage": 9.4,
      "regulatoryFeasibility": 8.8,
      "clinicalRisk": 5.2,
      "compositePrioritizationScore": 7.4,
      "narrative": "Potent bisphosphonate zoledronic acid provides sustained disease remission in Paget's disease with single infusion. Originally for cancer-related bone complications, its remarkable efficacy in this metabolic bone disorder demonstrates bisphosphonates' broad therapeutic potential.",
      "pubchemCid": "68740"
    },
    {
      "id": "37",
      "drugName": "Gabapentin",
      "drugNdcCode": "0071-0805-24",
      "diseaseName": "Restless Legs Syndrome",
      "diseaseOntologyTerm": "MONDO:0005375",
      "biologicalSuitability": 7.6,
      "unmetMedicalNeed": 7.5,
      "economicSuitability": 7.9,
      "marketSize": 7.1,
      "competitiveAdvantage": 7.3,
      "regulatoryFeasibility": 8.1,
      "clinicalRisk": 3.8,
      "compositePrioritizationScore": 7,
      "narrative": "Alpha-2-delta ligand gabapentin effectively reduces RLS symptoms and sleep disturbance. Its mechanism differs from dopamine agonists, providing alternative first-line therapy with lower augmentation risk, particularly beneficial for patients with painful neuropathy comorbidity.",
      "pubchemCid": "3446"
    },
    {
      "id": "38",
      "drugName": "Lisinopril",
      "drugNdcCode": "0071-0137-23",
      "diseaseName": "Diabetic Retinopathy",
      "diseaseOntologyTerm": "MONDO:0005260",
      "biologicalSuitability": 6.8,
      "unmetMedicalNeed": 8.3,
      "economicSuitability": 8.1,
      "marketSize": 8.4,
      "competitiveAdvantage": 6.2,
      "regulatoryFeasibility": 7.2,
      "clinicalRisk": 3.6,
      "compositePrioritizationScore": 7,
      "narrative": "ACE inhibitor lisinopril may slow diabetic retinopathy progression beyond blood pressure control through VEGF modulation. While benefits are modest compared to metabolic control, renin-angiotensin blockade offers adjunctive protection for this sight-threatening complication.",
      "pubchemCid": "5362119"
    },
    {
      "id": "39",
      "drugName": "Erythropoietin",
      "drugNdcCode": "55513-144-01",
      "diseaseName": "Amyotrophic Lateral Sclerosis",
      "diseaseOntologyTerm": "MONDO:0004976",
      "biologicalSuitability": 5.9,
      "unmetMedicalNeed": 9.7,
      "economicSuitability": 4.6,
      "marketSize": 6.2,
      "competitiveAdvantage": 6.5,
      "regulatoryFeasibility": 5.4,
      "clinicalRisk": 7.8,
      "compositePrioritizationScore": 6.6,
      "narrative": "Recombinant erythropoietin's neuroprotective and anti-apoptotic properties suggested promise in ALS. However, clinical trials have been disappointing, highlighting the challenge of translating preclinical neuroprotection to this relentlessly progressive motor neuron disease.",
      "pubchemCid": "16132341"
    },
    {
      "id": "40",
      "drugName": "Tetracycline",
      "drugNdcCode": "0093-1065-01",
      "diseaseName": "Bullous Pemphigoid",
      "diseaseOntologyTerm": "MONDO:0019318",
      "biologicalSuitability": 7.1,
      "unmetMedicalNeed": 7.8,
      "economicSuitability": 8.5,
      "marketSize": 5.6,
      "competitiveAdvantage": 7.2,
      "regulatoryFeasibility": 7.8,
      "clinicalRisk": 3.4,
      "compositePrioritizationScore": 6.8,
      "narrative": "Antibiotic tetracycline demonstrates immunomodulatory effects useful in mild-moderate bullous pemphigoid. Its steroid-sparing potential reduces toxicity in elderly patients prone to this autoimmune blistering disease, offering safer alternative to systemic immunosuppression.",
      "pubchemCid": "54675776"
    },
    {
      "id": "41",
      "drugName": "Methylphenidate",
      "drugNdcCode": "0406-0461-01",
      "diseaseName": "Cancer-Related Fatigue",
      "diseaseOntologyTerm": "MONDO:0044348",
      "biologicalSuitability": 6.4,
      "unmetMedicalNeed": 8.5,
      "economicSuitability": 6.9,
      "marketSize": 7.8,
      "competitiveAdvantage": 6.6,
      "regulatoryFeasibility": 6.2,
      "clinicalRisk": 5.1,
      "compositePrioritizationScore": 6.8,
      "narrative": "Psychostimulant methylphenidate offers short-term improvement in cancer-related fatigue through dopaminergic enhancement. While not addressing underlying causes, symptomatic relief can meaningfully impact quality of life during and after cancer treatment.",
      "pubchemCid": "4158"
    },
    {
      "id": "42",
      "drugName": "Warfarin",
      "drugNdcCode": "0056-0170-70",
      "diseaseName": "Calciphylaxis",
      "diseaseOntologyTerm": "MONDO:0001531",
      "biologicalSuitability": 5.6,
      "unmetMedicalNeed": 9.2,
      "economicSuitability": 7.4,
      "marketSize": 4.2,
      "competitiveAdvantage": 6.8,
      "regulatoryFeasibility": 5.6,
      "clinicalRisk": 8.1,
      "compositePrioritizationScore": 6.7,
      "narrative": "Paradoxically, anticoagulant warfarin may contribute to calciphylaxis through vitamin K depletion affecting matrix Gla protein. Case reports suggest benefit from warfarin cessation and vitamin K supplementation in this devastating vascular calcification syndrome.",
      "pubchemCid": "54678486"
    },
    {
      "id": "43",
      "drugName": "Prednisone",
      "drugNdcCode": "0054-4742-25",
      "diseaseName": "Sudden Sensorineural Hearing Loss",
      "diseaseOntologyTerm": "MONDO:0001083",
      "biologicalSuitability": 7.9,
      "unmetMedicalNeed": 8.4,
      "economicSuitability": 8.6,
      "marketSize": 6.7,
      "competitiveAdvantage": 7.7,
      "regulatoryFeasibility": 8.3,
      "clinicalRisk": 5.4,
      "compositePrioritizationScore": 7.6,
      "narrative": "Corticosteroid prednisone remains standard therapy for sudden hearing loss despite unclear mechanism. High-dose systemic or intratympanic administration improves hearing recovery rates, though spontaneous improvement complicates assessment of true treatment effects.",
      "pubchemCid": "5865"
    },
    {
      "id": "44",
      "drugName": "Lithium",
      "drugNdcCode": "0054-8775-25",
      "diseaseName": "Cluster Headache",
      "diseaseOntologyTerm": "MONDO:0001600",
      "biologicalSuitability": 7.2,
      "unmetMedicalNeed": 8.8,
      "economicSuitability": 7.3,
      "marketSize": 5.8,
      "competitiveAdvantage": 7.6,
      "regulatoryFeasibility": 7.1,
      "clinicalRisk": 6.2,
      "compositePrioritizationScore": 7.1,
      "narrative": "Mood stabilizer lithium effectively prevents cluster headache attacks through unclear mechanisms. Despite narrow therapeutic window and monitoring requirements, it remains valuable for chronic cluster patients, particularly those inadequately controlled by other preventives.",
      "pubchemCid": "11125"
    },
    {
      "id": "45",
      "drugName": "Furosemide",
      "drugNdcCode": "0054-3280-25",
      "diseaseName": "Hypercalcemia",
      "diseaseOntologyTerm": "MONDO:0002917",
      "biologicalSuitability": 7.4,
      "unmetMedicalNeed": 7.6,
      "economicSuitability": 8.7,
      "marketSize": 6.4,
      "competitiveAdvantage": 7.1,
      "regulatoryFeasibility": 8.4,
      "clinicalRisk": 4.8,
      "compositePrioritizationScore": 7.2,
      "narrative": "Loop diuretic furosemide promotes urinary calcium excretion in severe hypercalcemia. While less central since bisphosphonate availability, it remains useful adjunct in acute management, particularly when aggressive volume expansion and calciuresis are needed.",
      "pubchemCid": "3440"
    },
    {
      "id": "46",
      "drugName": "Dexamethasone",
      "drugNdcCode": "0054-3176-25",
      "diseaseName": "High Altitude Cerebral Edema",
      "diseaseOntologyTerm": "MONDO:0001725",
      "biologicalSuitability": 8.5,
      "unmetMedicalNeed": 8.9,
      "economicSuitability": 7.9,
      "marketSize": 4.9,
      "competitiveAdvantage": 8.8,
      "regulatoryFeasibility": 8.6,
      "clinicalRisk": 4.7,
      "compositePrioritizationScore": 7.5,
      "narrative": "Potent corticosteroid dexamethasone can be lifesaving in high altitude cerebral edema by reducing brain swelling. Used both for prevention and treatment when descent is impossible, it has become essential in high-altitude medicine despite non-specific mechanism.",
      "pubchemCid": "5743"
    },
    {
      "id": "47",
      "drugName": "Chlorpromazine",
      "drugNdcCode": "0641-1546-25",
      "diseaseName": "Intractable Hiccups",
      "diseaseOntologyTerm": "MONDO:0001912",
      "biologicalSuitability": 6.7,
      "unmetMedicalNeed": 7.2,
      "economicSuitability": 7.6,
      "marketSize": 4.6,
      "competitiveAdvantage": 8.2,
      "regulatoryFeasibility": 8.1,
      "clinicalRisk": 5.8,
      "compositePrioritizationScore": 6.9,
      "narrative": "First-generation antipsychotic chlorpromazine remains only FDA-approved medication for intractable hiccups. Its efficacy through central dopaminergic and cholinergic effects validates old empirical observations, though side effects limit use to truly refractory cases.",
      "pubchemCid": "2726"
    },
    {
      "id": "48",
      "drugName": "Allopurinol",
      "drugNdcCode": "0378-0043-01",
      "diseaseName": "Leishmaniasis",
      "diseaseOntologyTerm": "MONDO:0005773",
      "biologicalSuitability": 5.8,
      "unmetMedicalNeed": 8.6,
      "economicSuitability": 8.3,
      "marketSize": 5.2,
      "competitiveAdvantage": 6.4,
      "regulatoryFeasibility": 5.7,
      "clinicalRisk": 4.1,
      "compositePrioritizationScore": 6.3,
      "narrative": "Xanthine oxidase inhibitor allopurinol shows antiparasitic effects through purine metabolism disruption in Leishmania. While not first-line, it may have role as adjunctive oral therapy in regions with limited access to standard antimonial compounds.",
      "pubchemCid": "2094"
    },
    {
      "id": "49",
      "drugName": "Tranexamic Acid",
      "drugNdcCode": "0143-9285-01",
      "diseaseName": "Postpartum Hemorrhage",
      "diseaseOntologyTerm": "MONDO:0002309",
      "biologicalSuitability": 8.8,
      "unmetMedicalNeed": 9.3,
      "economicSuitability": 8.4,
      "marketSize": 7.6,
      "competitiveAdvantage": 8.9,
      "regulatoryFeasibility": 8.7,
      "clinicalRisk": 3.9,
      "compositePrioritizationScore": 8,
      "narrative": "Antifibrinolytic tranexamic acid reduces mortality from postpartum hemorrhage by 30% in large trials. This inexpensive generic drug's impact on maternal mortality worldwide represents one of most important recent advances in obstetric care, now WHO essential medicine.",
      "pubchemCid": "5526"
    },
    {
      "id": "50",
      "drugName": "Omega-3 Fatty Acids",
      "drugNdcCode": "0456-3505-60",
      "diseaseName": "Hypertriglyceridemia",
      "diseaseOntologyTerm": "MONDO:0002492",
      "biologicalSuitability": 7.7,
      "unmetMedicalNeed": 7.4,
      "economicSuitability": 7.1,
      "marketSize": 8.2,
      "competitiveAdvantage": 7.4,
      "regulatoryFeasibility": 8.5,
      "clinicalRisk": 2.6,
      "compositePrioritizationScore": 7,
      "narrative": "Prescription omega-3 fatty acids significantly reduce triglycerides through hepatic fatty acid oxidation and VLDL synthesis reduction. While cardiovascular outcome benefits remain debated, marked triglyceride lowering in severe hypertriglyceridemia prevents pancreatitis risk.",
      "pubchemCid": "445580"
    }
  ]
}